Kuyama S et al. – In the current study, S-1 with carboplatin was shown to be a reasonable treatment regimen in the elderly with advanced non-small-cell lung cancer (NSCLC).

Methods

• 33 patients with the following characteristics were enrolled in the study: previously untreated advanced NSCLC; wild-type epidermal growth factor receptor; greater than or equal to 70 years of age; and a performance status of 0–2.
• Induction consisted of oral S-1 (40?mg/m2 bid) for 2 weeks and carboplatin (area under the curve: 5) on day 1 every 4 weeks.
• Maintenance therapy consisted of S-1 alone (40?mg/m2 bid) was administered for 2 weeks every 4 weeks until disease progression.

Results

• The ORR was 30.3% and the disease control rate was 57.6%.
• The median PFS and OS were 134?days and 479?days, respectively.
• Low thymidine phosphorylase expression was associated with the disease control rate.